benzylideneacetone (t-PBO)
RN given refers to cpd without isomeric; structure in Merck Index, 9th ed, #1153
Also Known As:
t-PBO; 4-phenyl-3-buten-2-one; 4-phenylbutenone; benzalacetone; benzylideneacetone, (E)-isomer; benzylideneacetone, (Z)-isomer; trans-4-phenyl-3-buten-2-one; 3-buten-2-one, 4-phenyl-
Networked: 5
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Ahn, Sung K:
1 article
(11/2019)
|
2. | Choi, Chun Whan:
1 article
(11/2019)
|
3. | Choi, Yun-Hyeok:
1 article
(11/2019)
|
4. | Hong, Seong Su:
1 article
(11/2019)
|
5. | Kim, Hankyeom:
1 article
(11/2019)
|
6. | Kim, Hong Kyu:
1 article
(11/2019)
|
7. | Kim, Myung Hwan:
1 article
(11/2019)
|
8. | Kim, Woo Jung:
1 article
(11/2019)
|
9. | Ku, Jin-Mo:
1 article
(11/2019)
|
10. | Lee, Eun Jung:
1 article
(11/2019)
|
Related Diseases
1. | Neoplasms (Cancer)
01/24/2000
- " Structure-activity relationship in potentially anti-tumor promoting benzalacetone derivatives, as assayed by the epstein-barr virus early antigen activation." 11/01/1994
- " DCA did not alter the cytosolic activity for the GST substrates 1-chloro-2,4-dinitrobenzene (CDNB) or trans-4-phenyl-3-buten-2-one (tPBO) in tumors or surrounding liver. " 01/24/2000
- " The in vitro anti-tumor promoting activities of antimutagenic benzalacetone (4-phenyl-3-buten-2-one), its monosubstituted derivatives and related compounds, cinnamaldehydes and cinnamic acids, were evaluated by determining the inhibitory effect on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells. " 07/01/1994
- " Cytosolic glutathione S-transferase activity for trans-4-phenyl-3-buten-2-one in advanced tumors ranged from 42% to 66% of the activity in matched surrounding liver, whereas glutathione S-transferase activities for 1-chloro-2,4-dinitrobenzene were increased by 140% to 161%. " 12/11/1998
- " To elucidate the structure-activity relationship on the anti-tumor promoting activity, dehydrozingerone, curcumin, isoeugenol, which has no carbonyl group in the side chain, benzalacetone, which is the basic structure of dehydrozingerone, o-dehydrozingerone, which is the ortho-hydroxyl substituted compound of dehydrozingerone, and their related compounds were investigated using the in vitro short-term assay on TPA-induced EBV-EA activation. "
|
2. | Osteoporosis
|
|
Related Drugs and Biologics
Related Therapies and Procedures